CLL highlights at ASH 2022: clinical trial updates, novel BTK inhibitors & combination therapy

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, and Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center, New York, NY, who discuss recent updates in chronic lymphocytic leukemia (CLL). The experts comment on the role of doublet and triplet therapies in CLL, clinical trial updates, and further highlight the impact of novel Bruton’s tyrosine kinase (BTK) inhibitors in this space.

The post CLL highlights at ASH 2022: clinical trial updates, novel BTK inhibitors & combination therapy appeared first on VJHemOnc.